$3.75
Insights on Harvard Bioscience Inc
Revenue is up for the last 2 quarters, 25.36M → 28.15M (in $), with an average increase of 9.9% per quarter
Netprofit is down for the last 4 quarters, 622.0K → -1.81M (in $), with an average decrease of 110.2% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 25.6% return, outperforming this stock by 62.0%
In the last 3 years, Intuitive Surgical, Inc. has given 34.1% return, outperforming this stock by 80.7%
0.0%
Downside
Day's Volatility :7.29%
Upside
7.29%
8.27%
Downside
52 Weeks Volatility :45.22%
Upside
40.29%
Period | Harvard Bioscience Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.7% | -2.1% | 0.0% |
6 Months | -7.76% | 10.2% | 0.0% |
1 Year | -33.78% | 5.8% | 0.5% |
3 Years | -46.59% | 14.0% | -22.1% |
Market Capitalization | 157.2M |
Book Value | $1.68 |
Earnings Per Share (EPS) | -0.08 |
PEG Ratio | 2.89 |
Wall Street Target Price | 6.92 |
Profit Margin | -3.04% |
Operating Margin TTM | 3.14% |
Return On Assets TTM | 1.1% |
Return On Equity TTM | -4.7% |
Revenue TTM | 112.3M |
Revenue Per Share TTM | 2.65 |
Quarterly Revenue Growth YOY | -1.0% |
Gross Profit TTM | 62.3M |
EBITDA | 9.5M |
Diluted Eps TTM | -0.08 |
Quarterly Earnings Growth YOY | -0.8 |
EPS Estimate Current Year | 0.21 |
EPS Estimate Next Year | 0.29 |
EPS Estimate Current Quarter | 0.05 |
EPS Estimate Next Quarter | 0.04 |
What analysts predicted
Upside of 84.53%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 120.8M | ↑ 18.54% |
Net Income | -3.5M | ↑ 300.23% |
Net Profit Margin | -2.87% | ↓ 2.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 116.2M | ↓ 3.81% |
Net Income | -4.7M | ↑ 35.38% |
Net Profit Margin | -4.03% | ↓ 1.16% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 102.1M | ↓ 12.12% |
Net Income | -7.8M | ↑ 66.63% |
Net Profit Margin | -7.65% | ↓ 3.62% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 118.9M | ↑ 16.46% |
Net Income | -288.0K | ↓ 96.31% |
Net Profit Margin | -0.24% | ↑ 7.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 113.3M | ↓ 4.68% |
Net Income | -9.5M | ↑ 3204.17% |
Net Profit Margin | -8.4% | ↓ 8.16% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 112.3M | ↓ 0.96% |
Net Income | -3.4M | ↓ 64.11% |
Net Profit Margin | -3.04% | ↑ 5.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 26.9M | ↓ 7.83% |
Net Income | -3.4M | ↓ 239.84% |
Net Profit Margin | -12.65% | ↓ 20.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 28.4M | ↑ 5.59% |
Net Income | -1.7M | ↓ 51.07% |
Net Profit Margin | -5.86% | ↑ 6.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.0M | ↑ 5.45% |
Net Income | 622.0K | ↓ 137.33% |
Net Profit Margin | 2.08% | ↑ 7.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.8M | ↓ 4.06% |
Net Income | -980.0K | ↓ 257.56% |
Net Profit Margin | -3.41% | ↓ 5.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.4M | ↓ 11.81% |
Net Income | -1.2M | ↑ 26.43% |
Net Profit Margin | -4.89% | ↓ 1.48% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.2M | ↑ 11.0% |
Net Income | -1.8M | ↑ 46.73% |
Net Profit Margin | -6.46% | ↓ 1.57% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 168.1M | ↑ 53.7% |
Total Liabilities | 85.9M | ↑ 201.85% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 164.9M | ↓ 1.91% |
Total Liabilities | 83.2M | ↓ 3.16% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 156.3M | ↓ 5.23% |
Total Liabilities | 79.6M | ↓ 4.33% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 162.3M | ↑ 3.9% |
Total Liabilities | 78.9M | ↓ 0.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 145.4M | ↓ 10.46% |
Total Liabilities | 73.1M | ↓ 7.35% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 137.4M | ↓ 5.5% |
Total Liabilities | 64.3M | ↓ 12.1% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 147.0M | ↓ 5.32% |
Total Liabilities | 75.0M | ↓ 3.52% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 145.4M | ↓ 1.12% |
Total Liabilities | 73.1M | ↓ 2.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 145.6M | ↑ 0.15% |
Total Liabilities | 71.2M | ↓ 2.6% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 142.9M | ↓ 1.84% |
Total Liabilities | 67.5M | ↓ 5.23% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 139.7M | ↓ 2.21% |
Total Liabilities | 65.4M | ↓ 3.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 137.4M | ↓ 1.7% |
Total Liabilities | 64.3M | ↓ 1.77% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.3M | ↑ 121.76% |
Investing Cash Flow | -53.8M | ↑ 5766.52% |
Financing Cash Flow | 53.1M | ↓ 3060.55% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.0M | ↑ 243.3% |
Investing Cash Flow | -229.0K | ↓ 99.57% |
Financing Cash Flow | -7.6M | ↓ 114.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.3M | ↑ 15.96% |
Investing Cash Flow | -1.4M | ↑ 512.23% |
Financing Cash Flow | -8.0M | ↑ 4.47% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3M | ↓ 86.48% |
Investing Cash Flow | -1.3M | ↓ 4.07% |
Financing Cash Flow | -252.0K | ↓ 96.84% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2M | ↓ 8.72% |
Investing Cash Flow | -1.6M | ↑ 18.22% |
Financing Cash Flow | -2.8M | ↑ 1025.79% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 649.0K | ↓ 441.58% |
Investing Cash Flow | -442.0K | ↑ 0.0% |
Financing Cash Flow | 377.0K | ↓ 165.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.7M | ↑ 312.79% |
Investing Cash Flow | -235.0K | ↓ 46.83% |
Financing Cash Flow | -2.7M | ↓ 824.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.8M | ↓ 32.36% |
Investing Cash Flow | 288.0K | ↓ 222.55% |
Financing Cash Flow | -2.9M | ↑ 5.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.6M | ↑ 96.03% |
Investing Cash Flow | -625.0K | ↓ 317.01% |
Financing Cash Flow | -2.4M | ↓ 17.91% |
Sell
Neutral
Buy
Harvard Bioscience Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Harvard Bioscience Inc | -9.05% | -7.76% | -33.78% | -46.59% | 36.11% |
Intuitive Surgical, Inc. | -1.0% | 37.45% | 26.38% | 34.08% | 133.9% |
Resmed Inc. | 15.54% | 44.38% | -6.77% | 11.16% | 93.11% |
Becton, Dickinson And Company | -2.13% | -7.63% | -5.93% | -1.17% | 1.73% |
West Pharmaceutical Services Inc | -6.63% | 10.94% | -0.15% | 9.85% | 201.93% |
Alcon Ag | -4.08% | 9.15% | 7.34% | 14.61% | 37.85% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Harvard Bioscience Inc | NA | NA | 2.89 | 0.21 | -0.05 | 0.01 | NA | 1.68 |
Intuitive Surgical, Inc. | 67.57 | 67.57 | 7.13 | 6.28 | 0.16 | 0.08 | NA | 39.37 |
Resmed Inc. | 30.38 | 30.38 | 1.75 | 7.4 | 0.22 | 0.11 | 0.01 | 30.47 |
Becton, Dickinson And Company | 53.75 | 53.75 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
West Pharmaceutical Services Inc | 49.01 | 49.01 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 40.22 | 40.22 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Harvard Bioscience Inc | Buy | $157.2M | 36.11% | NA | -3.04% |
Intuitive Surgical, Inc. | Buy | $133.0B | 133.9% | 67.57 | 27.16% |
Resmed Inc. | Buy | $27.0B | 93.11% | 30.38 | 19.77% |
Becton, Dickinson And Company | Buy | $67.6B | 1.73% | 53.75 | 6.44% |
West Pharmaceutical Services Inc | Buy | $28.2B | 201.93% | 49.01 | 20.12% |
Alcon Ag | Buy | $38.9B | 37.85% | 40.22 | 10.3% |
B. Riley Asset Management, LLC
Punch & Associates Inv Mgmt Inc
BlackRock Inc
Harvey Partners LLC
AMH Equity Ltd
Vanguard Group Inc
Harvard Bioscience Inc’s price-to-earnings ratio stands at None
Read Moreharvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Organization | Harvard Bioscience Inc |
Employees | 391 |
CEO | Mr. James W. Green |
Industry | Health Technology |